Unione Europea -
norvegese -
EMA (European Medicines Agency)
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiske midler - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
Norvegia -
norvegese -
Statens legemiddelverk
sunitinib sandoz 12.5 mg
sandoz - københavn - sunitinib - kapsel, hard - 12.5 mg
Norvegia -
norvegese -
Statens legemiddelverk
sunitinib sandoz 25 mg
sandoz - københavn - sunitinib - kapsel, hard - 25 mg
Norvegia -
norvegese -
Statens legemiddelverk
sunitinib sandoz 50 mg
sandoz - københavn - sunitinib - kapsel, hard - 50 mg
Norvegia -
norvegese -
Statens legemiddelverk
sunitinib newbury 50 mg
newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 50 mg
Norvegia -
norvegese -
Statens legemiddelverk
sunitinib newbury 12.5 mg
newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 12.5 mg
Norvegia -
norvegese -
Statens legemiddelverk
sunitinib newbury 25 mg
newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 25 mg
Norvegia -
norvegese -
Statens legemiddelverk
sunitinib teva 12.5 mg
teva b.v. - sunitinib - kapsel, hard - 12.5 mg
Norvegia -
norvegese -
Statens legemiddelverk
sunitinib teva 25 mg
teva b.v. - sunitinib - kapsel, hard - 25 mg
Norvegia -
norvegese -
Statens legemiddelverk
sunitinib teva 50 mg
teva b.v. - sunitinib - kapsel, hard - 50 mg